Personalized medicine player Theranostics is in the midst of a modest fund raise – it’s raising $1 million in equity, according to a regulatory filing.
Not to be confused with biotech media darling Theranos – the Bay Area startup that means to do a wide range of testing form a single blood drop – Theranostics still wades in the same paddling pool: The Philadelphia company develops ways to measure the activation of signaling pathways necessary in molecular targeted therapies and companion diagnostics. The companies are so-named because of their sector, theranostics – the confluence of therapeutics and diagnostics.
This funding announcement comes on the heels of Theranostics’ Oct. 27 appointment of Luis T. Gutierrez as its president and CEO. Gutierrez is moving over from a VP stint at clinical research org Aptiv Solutions.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
More from MedCity News on Theranostics here.